Reference : Differentiation of patented crystalline glucosamine sulfate from other glucosamine pr...
Scientific journals : Article
Human health sciences : Orthopedics, rehabilitation & sports medicine
http://hdl.handle.net/2268/209592
Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment.
English
Saengnipanthkul, Sukit [> >]
Waikakul, Saranatra [> >]
Rojanasthien, Sattaya [> >]
Totemchokchyakarn, Kitti [> >]
Srinkapaibulaya, Attarit [> >]
Cheh Chin, Tai [> >]
Mai Hong, Nguyen [> >]
Bruyère, Olivier mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Cooper, Cyrus [> >]
Reginster, Jean-Yves mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Lwin, Myat [> >]
Mar-2017
International Journal of Rheumatic Diseases
Yes (verified by ORBi)
International
1756-1841
1756-185X
England
[en] glucosamine ; osteoarthritis ; symptomatic slow-acting drugs for osteoarthritis
[en] Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are recommended for the medium- to long-term management of knee osteoarthritis (OA) due to their abilities to control pain, improve function and delay joint structural changes. Among SYSADOAs, evidence is greatest for the patented crystalline glucosamine sulfate (pCGS) formulation (Mylan). Glucosamine is widely available as glucosamine sulfate (GS) and glucosamine hydrochloride (GH) preparations that vary substantially in molecular form, pharmaceutical formulation and dose regimen. Only pCGS is given as a highly bioavailable once-daily dose (1500 mg), which consistently delivers the plasma levels of around 10 mumol/L required to inhibit interleukin-1-induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction. Careful consideration of the evidence base reveals that only pCGS reliably provides a moderate effect size on pain that is higher than paracetamol and equivalent to non-steroidal anti-inflammatory drugs (NSAIDs), while non-crystalline GS and GH fail to reach statistical significance for pain reduction. Chronic administration of pCGS has disease-modifying effects, with a reduction in need for total joint replacement lasting for 5 years after treatment cessation. Pharmacoeconomic studies of pCGS demonstrate long-term reduction in additional pain analgesia and NSAIDs, with a 50% reduction in costs of other OA medication and healthcare consultations. Consequently, pCGS is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression. Physician and patient education on the differentiation of pCGS from other glucosamine formulations will help to improve treatment selection, increase treatment adherence, and optimize clinical benefit in OA.
http://hdl.handle.net/2268/209592
10.1111/1756-185X.13068
(c) 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations ....pdfPublisher postprint201.83 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.